These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32382008)

  • 21. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sophoridine inhibits lung cancer cell growth and enhances cisplatin sensitivity through activation of the p53 and Hippo signaling pathways.
    Zhu L; Huang S; Li J; Chen J; Yao Y; Li L; Guo H; Xiang X; Deng J; Xiong J
    Gene; 2020 Jun; 742():144556. PubMed ID: 32165304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiR-29c reduces the cisplatin resistance of non-small cell lung cancer cells by negatively regulating the PI3K/Akt pathway.
    Sun DM; Tang BF; Li ZX; Guo HB; Cheng JL; Song PP; Zhao X
    Sci Rep; 2018 May; 8(1):8007. PubMed ID: 29789623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The long intergenic noncoding RNA GAS5 reduces cisplatin-resistance in non-small cell lung cancer through the miR-217/LHPP axis.
    Yang X; Meng L; Zhong Y; Hu F; Wang L; Wang M
    Aging (Albany NY); 2021 Jan; 13(2):2864-2884. PubMed ID: 33418541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of RIF1 on response of non-small-cell lung cancer patients to platinum-based chemotherapy by regulating MYC signaling pathway.
    Mei Y; Liu YB; Hu DL; Zhou HH
    Int J Biol Sci; 2018; 14(13):1859-1872. PubMed ID: 30443189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncogene-induced senescence mediated by c-Myc requires USP10 dependent deubiquitination and stabilization of p14ARF.
    Ko A; Han SY; Choi CH; Cho H; Lee MS; Kim SY; Song JS; Hong KM; Lee HW; Hewitt SM; Chung JY; Song J
    Cell Death Differ; 2018 Jun; 25(6):1050-1062. PubMed ID: 29472714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.
    Jiang P; Wu X; Wang X; Huang W; Feng Q
    Oncotarget; 2016 Jul; 7(28):43337-43351. PubMed ID: 27270317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts.
    Némati F; Bras-Gonçalves R; Fontaine JJ; de Pinieux G; De Cremoux P; Chapelier A; Daniel C; Laurent-Puig P; Livartowski A; Judde JG; Bordier V; Poupon MF; Decaudin D
    Anticancer Drugs; 2009 Nov; 20(10):932-40. PubMed ID: 19741504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The deubiquitinase USP10 restores PTEN activity and inhibits non-small cell lung cancer cell proliferation.
    He Y; Jiang S; Mao C; Zheng H; Cao B; Zhang Z; Zhao J; Zeng Y; Mao X
    J Biol Chem; 2021 Sep; 297(3):101088. PubMed ID: 34416231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
    Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
    Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway.
    Lo Iacono M; Monica V; Vavalà T; Gisabella M; Saviozzi S; Bracco E; Novello S; Papotti M; Scagliotti GV
    Int J Cancer; 2015 Jun; 136(11):2598-609. PubMed ID: 25359574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
    Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
    Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
    Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
    Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer.
    Zhang K; Yang L; Wang J; Sun T; Guo Y; Nelson R; Tong TR; Pangeni R; Salgia R; Raz DJ
    Cell Commun Signal; 2019 Dec; 17(1):167. PubMed ID: 31842906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
    Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
    PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.